ID

40270

Description

Study ID: 111582 Clinical Study ID: 111582 Study Title: An Open Label Study to Examine the Effects of Low-fat and High-fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00821054 https://clinicaltrials.gov/ct2/show/NCT00821054 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Lapatinib Trade Name: N/A Study Indication: Neoplasms, Breast The study consists of a screening, four study visits at day-1, week 1, 2 and 3 and a follow-up visit. This document contains the data entry for the ECOG performance scale. It has to be filled in once for Screening, Visit day-1, week 1-3 and the follow-up visit. Week 3 assessments can be used as Follow-up assessments for subjects who have completed the 24 hour PK blood draw at the Week 3 visit and are proceeding into the continuing study EGF111767. Repeat as often as necessary in logs and repeats.

Lien

https://clinicaltrials.gov/ct2/show/NCT00821054

Mots-clés

Versions (2)

1. 26/03/2020 26/03/2020 - Christian Arras
2. 26/03/2020 26/03/2020 - Christian Arras

Détendeur de droits

GlaxoSmithKline

Téléchargé le

26 mars 2020

DOI

Pour une demande vous connecter.

Licence